Track MiMedx Group, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MiMedx Group, Inc. MDXG · Stock Open MiMedx Group, Inc. in new tab

4.27 USD
Add to portfolio
P/E
105.00
EPS
0.04
P/B
2.83
ROE
2.88
Beta
1.41
Target Price
7.00 USD
MiMedx Group, Inc. logo

MiMedx Group, Inc.

🧾 Earnings Recap – Q2 2026

Shares declined 2.1% following Q2 results and acquisition news as investors likely digested ongoing challenges in wound care despite surgical growth and the transformational Sanara MedTech deal.

  • Surgical revenue grew 15% year-over-year, continuing momentum from prior quarters.
  • Overall company revenue rose 9% sequentially from Q1 to Q2.
  • Wound care remains under pressure due to Medicare reimbursement changes causing market disruption.
  • The Sanara MedTech acquisition (~$35/share) will shift MiMedx's revenue mix to 75% surgical and 25% wound post-close.
  • Expected 2027 combined company revenue above $400 million with double-digit growth and adjusted EBITDA margin exceeding 20%, driven by $20 million in cost synergies.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 4, 2026
P/E105.00
EPS0.04
Book Value1.48
Price to Book2.83
Debt/Equity7.97
% Insiders2.144%
Growth
Revenue Growth-0.35%
Earnings Growth1.00%
Estimates
Forward P/E24.23
Forward EPS0.17
Target Mean Price7.00

DCF Valuation

Tweak assumptions to recompute fair value for MiMedx Group, Inc. (MDXG)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

MiMedx Group, Inc. Logo MiMedx Group, Inc. Analysis (MDXG)

United States Health Care Official Website Stock

Is MiMedx Group, Inc. a good investment? MiMedx Group, Inc. (MDXG) is currently trading at 4.27 USD. Market analysts have a consensus price target of 7.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 105.00. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: MiMedx Group, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is 0.17.

Investor FAQ

Does MiMedx Group, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is MiMedx Group, Inc.?

MiMedx Group, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of 0.04.

Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Exchange Ticker
NMS (United States) MDXG
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 2, 2008 0.320000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion